Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis

Aim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change, body weight normalisation, NASH-associated liver...

Full description

Saved in:
Bibliographic Details
Main Author: D. V. Garbuzenko
Format: Article
Language:Russian
Published: Gastro LLC 2022-01-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
non-alcoholic steatohepatitis
liver fibrosis
drug therapy
Online Access:https://www.gastro-j.ru/jour/article/view/646
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items